SEC Form 4 · accession 0001695028-26-000008
Oric Pharmaceuticals, Inc. · ORIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dominic Piscitelli
Officer — Chief Financial Officer
Period of report
Sep 24, 2026
Accepted (ET)
Sep 25, 2026 · 7:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001796280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 24, 2026 | M | 600 | $4.36 | A | 70,428 | D | |
| Common Stock | Sep 24, 2026 | S | 100 | $13.50 | D | 70,328 | D | |
| Common Stock | Sep 24, 2026 | S | 500 | $13.505 | D | 69,828 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $4.36 | Sep 24, 2026 | M | 600 | D | Jul 20, 2025 | Jul 19, 2032 | Common Stock | 600 | 91,900 | D |
Explanation of responses
- F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.